Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 85

Results For "first"

3332 News Found

Shilpa Medicare receives 8 observations from USFDA for Unit 4 at Jadcherla
Drug Approval | November 24, 2025

Shilpa Medicare receives 8 observations from USFDA for Unit 4 at Jadcherla

The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia


Mesoblast teams with NIH to launch pivotal trial of life-saving cell therapy in adults with severe aGvHD
Clinical Trials | November 24, 2025

Mesoblast teams with NIH to launch pivotal trial of life-saving cell therapy in adults with severe aGvHD

The therapy -- Ryoncil (remestemcel-L-rknd) -- will be tested in adults with severe steroid-refractory acute graft-versus-host disease


Cosmo and Glenmark receives market authorization of Winlevi in Europe
News | November 23, 2025

Cosmo and Glenmark receives market authorization of Winlevi in Europe

Winlevi is authorized in EU for the treatment of acne vulgaris


FDA approves combo therapy for Cisplatin-ineligible muscle-invasive bladder cancer patients
Drug Approval | November 23, 2025

FDA approves combo therapy for Cisplatin-ineligible muscle-invasive bladder cancer patients

The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy


AstraZeneca to invest $2 billion in Maryland manufacturing expansion
News | November 22, 2025

AstraZeneca to invest $2 billion in Maryland manufacturing expansion

The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan


AbbVie’s EPKINLY gains FDA nod for relapsed follicular lymphoma, offering new hope for patients
Drug Approval | November 21, 2025

AbbVie’s EPKINLY gains FDA nod for relapsed follicular lymphoma, offering new hope for patients

The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study


Merck’s two-drug HIV regimen hits phase 3 success
Clinical Trials | November 21, 2025

Merck’s two-drug HIV regimen hits phase 3 success

The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks


GSK teams up with LTZ Therapeutics to launch next-generation cancer therapies
R&D | November 21, 2025

GSK teams up with LTZ Therapeutics to launch next-generation cancer therapies

The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy


Alkem launches globally acclaimed De Simone Probiotic in India, expands GI portfolio
News | November 21, 2025

Alkem launches globally acclaimed De Simone Probiotic in India, expands GI portfolio

The formulation is backed by over 80 clinical trials and 200 scientific publications